# prostate cancer FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/prostate-cancer

> 4 upcoming FDA catalysts in prostate cancer: AAA817 (NVS) on Jun to Sep 2028 (topline data readout); AAA817 (NVS) on June 2028 (primary completion); AAA817 (NVS) on Sep to Dec 2028 (topline data readout); AAA817 (NVS) on September 2028 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Oct 2022 | [JANX007 trial start](https://sec-api.dev/pdufa/janx007) | JANX | prostate cancer | completed | "In October 2022, the first patient was dosed with our PSMA-TRACTr (JANX007) in our first-in-human Phase 1 clinical trial in patients with prostate cancer." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1817713/000095017025029177/janx-20241231.htm)) |
| February 18, 2026 | [Talazoparib plus enzalutamide primary completion](https://sec-api.dev/pdufa/talazoparib-plus-enzalutamide) | PFE | Prostate Cancer | completed | "NCT04821622 (Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-02-18 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04821622)) |
| March 2026 | [Truqap (capivasertib) primary completion](https://sec-api.dev/pdufa/capivasertib) | AZN | Prostate Cancer | delayed | "NCT05348577 (Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-03-04 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05348577)) |
| Jun to Sep 2028 | [AAA817 topline data readout](https://sec-api.dev/pdufa/aaa817) | NVS | Prostate Cancer | scheduled | "NCT06780670 (Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-06-27 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06780670)) |
| June 2028 | [AAA817 primary completion](https://sec-api.dev/pdufa/aaa817) | NVS | Prostate Cancer | scheduled | "NCT06780670 (Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-06-27 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06780670)) |
| Sep to Dec 2028 | [AAA817 topline data readout](https://sec-api.dev/pdufa/aaa817) | NVS | Prostate Cancer | scheduled | "NCT06855277 (Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-29 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06855277)) |
| September 2028 | [AAA817 primary completion](https://sec-api.dev/pdufa/aaa817) | NVS | Prostate Cancer | scheduled | "NCT06855277 (Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-29 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06855277)) |

## Drugs

- [JANX007](https://sec-api.dev/pdufa/janx007) (JANX)
- [Talazoparib plus enzalutamide](https://sec-api.dev/pdufa/talazoparib-plus-enzalutamide) (PFE)
- [Truqap (capivasertib)](https://sec-api.dev/pdufa/capivasertib) (AZN)
- [AAA817](https://sec-api.dev/pdufa/aaa817) (NVS)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/prostate-cancer.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "prostate cancer FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/prostate-cancer

```bibtex
@misc{secapidev_indications_prostate_cancer_20261116,
  title        = {prostate cancer FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/prostate-cancer}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_prostate_cancer_20261116","title":"prostate cancer FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/prostate-cancer","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
